2000
Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness M, Kenney J, Reiss M, Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Research 2000, 60: 5354-8. PMID: 11034070.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusPosttransplant lymphoproliferative disorderLymphoproliferative disordersBcl-2 antisenseLymphoproliferative diseaseImmunodeficient miceEpstein-Barr virus-associated lymphoproliferative diseaseBcl-2EBV-positive lymphoproliferative diseaseSequence-dependent antitumor effectsMajority of EBVAntisense oligodeoxynucleotide therapyEBV-positive malignanciesB-cell lymphoproliferationBcl-2 antisense therapyInhibition of proliferationLymphoblastoid B cellsTreatment strategiesChemoprotective effectsAntitumor effectsVitro treatmentB cellsChimeric modelDecreased expressionRational target
1996
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Of Clinical Oncology 1996, 14: 1943-9. PMID: 8656264, DOI: 10.1200/jco.1996.14.6.1943.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidFemaleHerpesvirus 4, HumanHumansImmunosuppressive AgentsLymphoproliferative DisordersMaleMethotrexateMiddle AgedConceptsEpstein-Barr virusMTX withdrawalLymphoproliferative disordersComplete remissionPolymerase chain reactionRheumatic diseasesPartial responseAbsence of EBVNegative Epstein-Barr virusEBV RNA transcriptsSpontaneous complete remissionLow-grade lymphomaCNS involvementExtranodal diseaseImmunosuppressive therapyMethotrexate therapyMTX therapyInitial managementAggressive lymphomaClinicopathologic featuresHodgkin's diseasePathologic findingsRheumatoid arthritisSitu hybridization studiesSpontaneous regression